American consumers and American taxpayers lose out on lower-cost generic drugs to the tune of billions of dollars each year.
this bill that Senator Grassley and I have that has bipartisan support would not affect the vast majority of the drug se...
Let's be very clear about what these deals are all about.
allows operating companies to exploit the lack of transparency in patent ownership to win a tactical advantage that coul...
We are also a strong supporter of another bipartisan bill, Senate bill 504, the Fair and Immediate Release of Generics A...
Hatch-Waxman is supposed to be about--at least paragraph 4 certifications--challenging invalid or not infringed patents.
In fact, after the Supreme Court ruling, an industry analyst said in a CNBC interview that the court created a 'holy mes...
that these particular type of settlements are delaying entry into the market and hurting consumers and the U.S. Governme...
To me, when you look at the numbers and the change since those Circuit Court decisions, this is more than just about som...
I think they assume that because for a number of years they were settled without pay for delay.
We urge Congress to take action on Senate bill 214, the Preserve Access to Affordable Generics Act.